Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme

Showing 21 to 30 of 32

TitleReference numberPublishedLast updated
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanomaTA766
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA709
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapyTA692
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancerTA683
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)TA674
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinomaTA661
Pembrolizumab with axitinib for untreated advanced renal cell carcinomaTA650
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal)TA570
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancerTA531
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapyTA428

Results per page

  1. 10
  2. 25
  3. 50
  4. All